SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

The Evaluation of the Relationship Between Albuminuria and Serum Asymmetric Dimethyl Arginine Level in Type-2 Diabetes Mellitus

Meltem GÜRSU
Aysegül SAKİN
Ahmet BEHLÜL
Savaş ÖZTÜRK
Egemen CEBECİ
Mehmet Selim ASLAN
Namık YİĞİT
Pages
16–20
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thismay show the increased risk of progressive kidney disease in these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Asymmetrical dimethyl arginine (ADMA) inhibits nitric oxide synthase causing a decline in nitric oxidelevels and so endothelial dysfunction.
📊
Key Findings & Data:In our study, we analyzed the relationship between albuminuria and ADMA levelin type-2 diabetes mellitus (DM).Methods: This is a cross sectional study in which 55 type 2 diabetic patients followed up in diabetes outpatient clinic.
💡
Conclusion & Impact:Thismay show the increased risk of progressive kidney disease in these patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Asymmetrical dimethyl arginine (ADMA) inhibits nitric oxide synthase causing a decline in nitric oxidelevels and so endothelial dysfunction. In our study, we analyzed the relationship between albuminuria and ADMA levelin type-2 diabetes mellitus (DM).Methods: This is a cross sectional study in which 55 type 2 diabetic patients followed up in diabetes outpatient clinic. Patients were divided into three groups according to albuminuria: normoalbuminuric (Group-1), microalbumiuric(Group-2) and macroalbuminuric (Group-3) patients. ADMA level was measured by ELISA method.Results: A total of 36 (65.45%) patients were female. The median age of patients were 59.9 years. There was no statistically significant difference between groups regarding age, duration of DM, gender, LDL cholesterol and body massindex. The median ADMA level was lower in Group-1 compared to Group-2 and Group-3. ADMA level was significantlycorrelated with albuminuria. Albuminuria was the only parameter related with ADMA in linear regression analysis.Conclusion: ADMA level is significantly increased even in microalbumiuric stage among patients with type 2 DM. Thismay show the increased risk of progressive kidney disease in these patients.

🔖

Cite This Article

GÜRSU, M., SAKİN, A., BEHLÜL, A., ÖZTÜRK, S., CEBECİ, E., ASLAN, M. S., YİĞİT, N. (2022). The Evaluation of the Relationship Between Albuminuria and Serum Asymmetric Dimethyl Arginine Level in Type-2 Diabetes Mellitus. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 16–20. https://ajindex.com/articles/508610

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004;53:1574–9
  2. Pugliese G. Updating the natural history of diabetic nephropathy. Acta Diabetol 2014;51:905–15
  3. Sakin A, Sahin S, Behlul A, Sumnu A, Gursu M, Sakin A, et al. The association of Visfatin levels with metabolic parameters and inflammation in diabetic nephropathy. Eastern J Med 2020;25:218–24
  4. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413–8
  5. Islam MR, Sultana N, Sutradhar SR, Asaduzzaman M. Prevalence of Diabetic Nephropathy in Patients Attending the Endocrine Department of Mymensingh Medical College Hospital. Mymensingh Med J 2020;29:530–8
  6. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746–52
  7. Bernatchez PN, Bauer PM, Yu J, Prendergast JS, He P, Sessa WC. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci U S A 2005;102:761–6
  8. Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006;189:236–40
  9. Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003;52:303–7
  10. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006;184:383–8
  11. American Diabetes A. Executive summary: Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S5–13
  12. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455–9
  13. Konukoglu D, Uzun H, Firtina S, Cigdem Arica P, Kocael A, Taskin M. Pla